Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Terminated 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 289Carcinoma, Non-Small-Cell Lung 236Neoplasms 189Prostatic Neoplasms 188Lung Neoplasms 147Multiple Myeloma 143Neoplasm Metastasis 106Colorectal Neoplasms 95Melanoma 93Ovarian Neoplasms 87Leukemia, Myeloid, Acute 79Lymphoma 73Leukemia, Lymphocytic, Chronic, B-Cell 73Brain Neoplasms 69Pancreatic Neoplasms 67Carcinoma, Renal Cell 64Hematologic Neoplasms 60Squamous Cell Carcinoma of Head and Neck 58Carcinoma, Hepatocellular 58Urinary Bladder Neoplasms 57Lymphoma, Non-Hodgkin 57Glioblastoma 55Triple Negative Breast Neoplasms 54Head and Neck Neoplasms 53Recurrence 51Lymphoma, Follicular 50Uterine Cervical Neoplasms 49Glioma 46Small Cell Lung Carcinoma 45Sarcoma 45

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Pathologic Processes × 90 days × Clear all
NCT05797246 2026-05-22

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
21 enrolled

DNA Virus Infections, Infections, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Pathologic Processes, Recurrence, Respiratory Tract Diseases, Respiratory Tract Infections, Tumor Virus Infections, Virus Diseases, Neoplasms, Squamous Cell, Disease Attributes, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡